BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25427165)

  • 21. Synergistic effect of KIR ligands missing and cytomegalovirus reactivation in improving outcomes of haematopoietic stem cell transplantation from HLA-matched sibling donor for treatment of myeloid malignancies.
    Cardozo DM; Marangon AV; da Silva RF; Aranha FJP; Visentainer JEL; Bonon SHA; Costa SCB; Miranda ECM; de Souza CA; Guimarães F
    Hum Immunol; 2016 Oct; 77(10):861-868. PubMed ID: 27394130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Influence of donor activating or inhibitory KIR on prognosis of unmanipulated allogeneic hematopoietic stem cell transplantation].
    Liang ZY; Ren HY; Cen XN; Qiu ZX; Wang LH; Ou JP; Li Y; Wang MJ; Wang WS; Xu WL; Dong YJ; Yin Y; Sun YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):155-60. PubMed ID: 23484711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
    Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H
    Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA-C matching and liver transplants: donor-recipient genotypes influence early outcome and CD8+KIR2D+ T-cells recuperation.
    López-Alvarez MR; Moya-Quiles MR; Minguela A; Gil J; Miras M; Campillo JA; Díaz-Alderete MA; García-Alonso AM; Sánchez-Bueno F; Vicario JL; Muro M; Alvarez-López MR
    Transplantation; 2009 Aug; 88(3 Suppl):S54-61. PubMed ID: 19667963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KIR gene and KIR ligand analysis to predict graft rejection after renal transplantation.
    Kreijveld E; van der Meer A; Tijssen HJ; Hilbrands LB; Joosten I
    Transplantation; 2007 Oct; 84(8):1045-51. PubMed ID: 17989611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
    Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation.
    Hadaya K; de Rham C; Bandelier C; Bandelier C; Ferrari-Lacraz S; Jendly S; Berney T; Buhler L; Kaiser L; Seebach JD; Tiercy JM; Martin PY; Villard J
    Am J Transplant; 2008 Dec; 8(12):2674-83. PubMed ID: 19032228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients.
    Stern M; Elsässer H; Hönger G; Steiger J; Schaub S; Hess C
    Am J Transplant; 2008 Jun; 8(6):1312-7. PubMed ID: 18444913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.
    Clausen J; Wolf D; Petzer AL; Gunsilius E; Schumacher P; Kircher B; Gastl G; Nachbaur D
    Clin Exp Immunol; 2007 Jun; 148(3):520-8. PubMed ID: 17493020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
    Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytomegalovirus and cancer after kidney transplantation: Role of the human leukocyte antigen system?
    Wong G; Chakera A; Chapman JR; Chadban SC; Pilmore H; Craig JC; Lim WH
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27860123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of the natural killer cell KIR repertoire by cytomegalovirus infection.
    Charoudeh HN; Terszowski G; Czaja K; Gonzalez A; Schmitter K; Stern M
    Eur J Immunol; 2013 Feb; 43(2):480-7. PubMed ID: 23161492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Missing Self-Induced Microvascular Rejection of Kidney Allografts: A Population-Based Study.
    Callemeyn J; Senev A; Coemans M; Lerut E; Sprangers B; Kuypers D; Koenig A; Thaunat O; Emonds MP; Naesens M
    J Am Soc Nephrol; 2021 Aug; 32(8):2070-2082. PubMed ID: 34301794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
    Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C
    Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients.
    Varga M; Rajczy K; Telkes G; Hídvégi M; Péter A; Remport A; Korbonits M; Fazakas J; Toronyi E; Sárváry E; Kóbori L; Járay J
    Nephrol Dial Transplant; 2008 Aug; 23(8):2673-8. PubMed ID: 18332066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of cytomegalovirus infection with human leukocyte antigen genotypes in recipients after allogeneic liver transplantation.
    Fan J; Meng XQ; Yang MF; Zhou L; Chen XM; Hu MJ; Fan WW; Ma WH; Li LJ
    Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):34-8. PubMed ID: 16481279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KIR/HLA ligand incompatibility in kidney transplantation.
    Kunert K; Seiler M; Mashreghi MF; Klippert K; Schönemann C; Neumann K; Pratschke J; Reinke P; Volk HD; Kotsch K
    Transplantation; 2007 Dec; 84(11):1527-33. PubMed ID: 18091530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KIR and HLA interactions are associated with control of primary CMV infection in solid organ transplant recipients.
    van Duin D; Avery RK; Hemachandra S; Yen-Lieberman B; Zhang A; Jain A; Butler RS; Barnard J; Schold JD; Fung J; Askar M
    Am J Transplant; 2014 Jan; 14(1):156-62. PubMed ID: 24369024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.